(Date:9/4/2008)... may be shortchanging their golden years by tappin...iversity of Illinois expert who has studied the fe..., More than three of every four Americans trim th...iming benefits early, a choice many might forego i... consequences, law professor Richard L. Kaplan say...
(Date:9/4/2008)...ncology contract research organization, has publis...uanced Approach to Get Into the Clinic Faster.&quo...al research scientist with 35 years of experience,...mmonly viewed as straightforward investigations ru...rue integration with preclinical, regulatory and c...
(Date:9/4/2008)...NORWICH, England and ONGAR, Ireland,Sept. 4 /PRNe...ofield Media,Europe Ltd, announced on the 29th Aug... publication from Silverdog Publishing., Health a... the iconic,Health and Safety at Work Act 1974 and.... It has been relied upon by blue-chip corporates,...
(Date:9/4/2008)...-FirstCall/ -- ULURU Inc. (Amex:,ULU) today announ...Weisel,Partners Healthcare Conference at 3:15 p.m....out ULURU Inc.:, ULURU Inc. is an emerging specia...ent of a portfolio of wound management, plastic su...nd consumers improved clinical,outcomes through co...
Breaking Medicine News(10 mins):Health News:New guide explores making the most of Social Security 2Health News:New guide explores making the most of Social Security 3Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 2Health News:Oncology Clinical Research Scientist Recommends a Nuanced Preclinical Study Process to Speed Drug Development 3Health News:Schofield Publishing Enters the Newsletter Market 2...l compound, CDDO-Im, shown to possess strong anti-...dels could soon revolutionize the treatment of liv... to increase the intrinsic resistance to carcinoge...unction of enzymes that remove toxins from the bod...
...esponse of MPs in favor of the proposed smoking ba...oking ban law would be imposed by the summer of ne...4 Vs 184 has been achieved when the issue of smoki...and pubs were taken up for consideration. Followin...
...l College Teachers Association (KGMCTA) on Friday ...the death // of a boy, Shyam, at the Medical Col...med that the death was caused due to the administr...the statement from the KGMCTA, Shyam, who was suff...
...ed to liver malfunction and now it has another dan... by French scientists it has been found that alcoh... that is responsible for many types of cancer. Sci...raises risk of cancer of the mouth, larynx, oesoph...
Other Medicine News:Health News:New Compound Offers Hope In Liver Cancer Treatment 2(Date:9/4/2008)...e with Two Abstracts Accepted for Presentation..., BRIDGEWATER, N.J., Sept. 4 /- Aege...ical company focused on the treatment of,cardiovas...ppointment of,Peter L. Garrambone, Jr. to the Comp...eer includes more than 50 pharmaceutical,transacti...
(Date:9/3/2008)...g Children Studied. Wrong,Conclusions Reached., N...ters for Disease,Control and Prevention (CDC) stud...he MMR vaccine and autism. The National Autism Ass...pel the growing public concern over a,vaccine-auti...ing design,and methodology., For years, parents h...
(Date:9/3/2008)...Research and Education Foundation,s Within Our Re...ing, Treating and Understandin...rst time during its,unprecedented initiative to fi...ollege of Rheumatology Research and Education Foun...research funded by the Within Our,Reach: Finding a...
(Date:9/3/2008)...ar Disease Awareness Month, CHARLOTTESVILLE, Va.,...,LLC, a clinical-stage drug-development company co... medical needs, announced today that it has begun,...of its lead drug,candidate trans sodium crocetinat...clinicaltrials.gov Website, is investigating TSC a...
Breaking Medicine Technology:Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2CDC Misses Target With Flawed MMR/Autism Study 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4ABR Affinity BioReagents Participates in the 2008 Fisher Scientific Supplier Expo in San Antonio Texas 10943 1ABR Affinity BioReagents Participates in the 2008 Fisher Scientific Supplier Expo in San Antonio Texas 10943 2ATS Medical Expects Fourth Quarter Revenue to Increase by Approximately 32 25 10941 1ATS Medical Expects Fourth Quarter Revenue to Increase by Approximately 32 25 10941 2Rochester Medical Reports 31 25 Increase in Branded Sales Resulting in 9 25 Overall Sales Growth for the First Quarter 2991 1Rochester Medical Reports 31 25 Increase in Branded Sales Resulting in 9 25 Overall Sales Growth for the First Quarter 2991 2Rochester Medical Reports 31 25 Increase in Branded Sales Resulting in 9 25 Overall Sales Growth for the First Quarter 2991 3Rochester Medical Reports 31 25 Increase in Branded Sales Resulting in 9 25 Overall Sales Growth for the First Quarter 2991 4Rochester Medical Reports 31 25 Increase in Branded Sales Resulting in 9 25 Overall Sales Growth for the First Quarter 2991 5Rochester Medical Reports 31 25 Increase in Branded Sales Resulting in 9 25 Overall Sales Growth for the First Quarter 2991 6Rochester Medical Reports 31 25 Increase in Branded Sales Resulting in 9 25 Overall Sales Growth for the First Quarter 2991 7CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology 2989 1CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology 2989 2CV Therapeutics and Medlogics Device Corporation Sign Licensing Agreement for CVTs Innovative Stent Coating Technology 2989 3Recommended for aqueous samples of moderate viscosity and density. Proven ergonomic design reduces hand fatigue, prevents injury. Dry seal technology. No cleaning, no greasing. Volume Range (ul)
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,411-9) or contact custom
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL.
Our variable volume Finnpipette Techpette combines form and function in a high performance pipette. Advanced pipetting technology, plus a colour-coded volume range, ensures quality, safety, comfort a
Medicine Products: